Zdrowie i gospodarka · 14.08.2014
Revised Draft Guidance for Industry on Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products-Considerations, Content, and Format; Availability
The Food and Drug Administration (FDA) is announcing the availability of a revised draft guidance for industry entitled "Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products--Considerations, Content, and Format." This draft guidance is one of a series of guidance documents intended to assist applicants in complying with FDA regulations on the content and format of labeling for human prescription drug and biological products. The guidance describes the recommended information to include in the Clinical Pharmacology section of labeling that pertains to the safe and effective use of human prescription drug and biological products. This revised draft guidance replaces the 2009 draft guidance for industry entitled "Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products--Content and Format."